Negative in Ames, in vitro chromosomal aberration and rat micronucleus assays
“Ponesimod was negative in in vitro (Ames, chromosomal aberration in mammalian cells) and in vivo (micronucleus in rat) assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Carcinogenicity
2-year rat: no drug-related tumors; mouse: hemangiomas/hemangiosarcomas at all doses in males and high-dose females
“In the 2-year rat carcinogenicity study, there were no drug-related increases in neoplasms in M or F. The mouse study was positive for hemangiomas and hemangiosarcomas, with an increase in incidences at all doses in M and in HDF.”
✓ VerifiedFDA pharmacology/toxicology review, p. 11Source ↗
Reproductive & developmental
Fertility unaffected in rats (NOAEL 100 mg/kg/day); rat and rabbit EFD: teratogenicity and fetal lethality
“In the reproductive and development studies with oral ponesimod, fertility was not affected in F or M (NOAEL was 100 mg/kg/day), but teratogenicity and fetal lethality was observed in both rats and rabbits.”
✓ VerifiedFDA pharmacology/toxicology review, p. 11Source ↗
Safety pharmacology
Single dose decreased heart rate and blood pressure and caused first- to third-degree AV block in guinea pigs
“In cardiovascular safety pharmacology studies, a single oral dose of ponesimod decreased heart rate, blood pressure, and caused first-, second-, and third-degree AV block in guinea pigs.”
✓ VerifiedFDA pharmacology/toxicology review, p. 10Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative